Canaccord analyst William Plovanic lowered the firm’s price target on AtriCure (ATRC) to $53 from $64 and keeps a Buy rating on the shares. The firm said they reported Q4 revenue results in line with its January preannouncement and reiterated its previously issued 2026 guidance and they continue to view the company as well positioned from a defensibility standpoint, particularly given its demonstrated ability to withstand prior competitive entry from Medtronic (MDT).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC:
- AtriCure: Sustained Outperformance, Manageable Competition, and Undervalued Growth Support Buy Rating and $54 Target
- Oppenheimer downgrades AtriCure on new competition from Edwards
- AtriCure downgraded to Perform from Outperform at Oppenheimer
- AtriCure price target lowered to $52 from $60 at Citizens
- Closing Bell Movers: Palo Alto Networks down 8% on soft guidance